Retacrit epoetin zeta regulatory update

The European Medicines Agency's CHMP issued a positive opinion on an MAA from Hospira for subcutaneous Retacrit epoetin zeta to treat renal anemia. Hospira markets an IV formulation of the biosimilar ...